Navigation Links
PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
Date:9/9/2011

ANNAPOLIS, Md., Sept. 9, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax™.  In addition to completing initial technology transfer at the 100 liter scale and demonstrating 36 month stability, the Company announced today that it has now completed a 1,500 liter engineering production run for SparVax™.  As a result, PharmAthene has shown it is able to produce bulk drug substance for SparVax™ at the final commercial scale for the product.

Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer, remarked, "PharmAthene has developed a robust manufacturing process for SparVax™ with the capability to produce more than 200 million rPA vaccine equivalent doses of bulk drug substance at the 50 mcg dose range on an annual basis.  The use of recombinant vaccine technology employing modern, industrial biotechnology manufacturing processes provides the flexibility to rapidly scale-up production in the event of a national emergency, which should enable a much more refined and cost-effective vaccine for the U.S. government and its citizens."

"As we remember and honor those who tragically lost their lives on September 11, 2001, we must not forget that it was also 10 years ago that our nation was introduced to the specter of biological terrorism in the form of the anthrax letter attacks.  Since those tragic events, our government has dedicated unprecedented resources to ensuring our nation's preparedness against future bioterrorism events," remarked Eric I. Richman, President and Chief Executive Officer for PharmAthene.  

"Recently, the Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services (HHS) released The Public Health
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
2. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
5. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
6. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
7. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
10. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
11. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Carolina (PRWEB) May 01, 2015 Spirax ... services, is extremely proud to announce that for the ... named as a winner of a Queen’s Award for ... for the design and manufacture of a unique flowmeter. ... the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research and ... million, compared to $8.0 million during the same period in ... $8.9 million, or $0.23 per basic and diluted share. This ... in 2014, of $8.7 million, or $0.27 per basic share ... equivalents and investments totaled $117.5 million. , "During the ...
(Date:4/30/2015)... April 30, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... agreement with Celula, Inc., a diagnostic testing company focused ... better patient care and improved outcomes.  Proceeds of the ... expand the commercialization of its products in the U.S. ...
(Date:4/30/2015)... 30, 2015  The Paul G. Allen Family Foundation ... grants to six groups of researchers with projects at ... in neuroscience: growing mature human brain cells in the ... $7.5 million over three years.  "This ... is especially significant because the field of neuronal maturation ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Oxford Finance Provides $10 Million Debt Financing to Celula 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5
... Participate at the "Facing ... JERUSALEM, Israel, May 6 Oramed,Pharmaceuticals, Inc. (OTCBB: ... for the first annual Presidential conference, "Facing,Tomorrow," as one ... of Israel. The monumental event is being held to ...
... May 5 NeoGenomics, Inc. (OTC,Bulletin Board: NGNM) announced today ... on Wednesday, May 7, 2008., The Company has ... results on May 7, 2008, at 11:00 AM EDT. ... at least,five minutes prior to the call. A replay ...
... (NYSE: BSX ) announced today that a ... its ruling in an,arbitration between the Company and ... to the 2005 settlement agreement between,the companies, alleged ... U.S. and European patents held by Medinol. The,arbitrators ...
Cached Biology Technology:Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule 2NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of interesting ?and potentially life-saving ?biological molecules. But tracking ... can be time-consuming, expensive and unreliable. , Now Salk ... of the rainforest and into the lab. Their findings ... journal Nature. , Stéphane Richard, Joseph Noel and Tomohisa ...
... reports ?one from Louisiana, one from Japan and ... pointing to involvement of endocannabinoids as a novel ... applications in eating, disease treatment and social behavior. ... The team from Tulane and Louisiana State Universities, ...
... to one another through the routine exchange of electrical ... the higher regions of the brain - regions that ... dialogue - apparently lose their ability to communicate effectively, ... in the journal Science, a team of researchers led ...
Cached Biology News:Stem cell training program to make its Stanford debut 2Stem cell training program to make its Stanford debut 3Endocannabinoids ?the brain's cannabis ?demonstrate novel modes of action to stress 2Frog peptides block HIV in lab study 2Frog peptides block HIV in lab study 3
... EKMax™ is a recombinant preparation of ... EKMax™ Enterokinase is expressed and isolated from ... highly purified enzyme preparation (2). It recognizes ... bond after the lysine residue. The enzyme ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
...
...
Biology Products: